Abstract
Prostate cancer is the second leading cause of cancer-related deaths in men in the United States. The role of the prostate-specific antigen in metastatic castrate-resistant prostate cancer has become more defined through the years. This article addresses how prostate-specific antigen criteria alone should not be used as a disease marker to discontinue therapy in metastatic castration-resistant disease.
| Original language | English |
|---|---|
| Pages (from-to) | 224-228 |
| Number of pages | 5 |
| Journal | Southern Medical Journal |
| Volume | 108 |
| Issue number | 4 |
| DOIs | |
| State | Published - 9 Apr 2015 |
Keywords
- PSAWG1
- PSAWG2
- androgen receptor
- metastatic castration resistant
- prostate-specific antigen